MicroRNA-210 regulates the metabolic and inflammatory status of primary human astrocytes.
Astrocyte
Hypoxia
Inflammation
Ischemia
MicroRNA-210
Multiple sclerosis
Stroke
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
06 Jan 2022
06 Jan 2022
Historique:
received:
21
09
2021
accepted:
27
12
2021
entrez:
7
1
2022
pubmed:
8
1
2022
medline:
1
4
2022
Statut:
epublish
Résumé
Astrocytes are the most numerous glial cell type with important roles in maintaining homeostasis and responding to diseases in the brain. Astrocyte function is subject to modulation by microRNAs (miRs), which are short nucleotide strands that regulate protein expression in a post-transcriptional manner. Understanding the miR expression profile of astrocytes in disease settings provides insight into the cellular stresses present in the microenvironment and may uncover pathways of therapeutic interest. Laser-capture microdissection was used to isolate human astrocytes surrounding stroke lesions and those from neurological control tissue. Astrocytic miR expression profiles were examined using quantitative reverse transcription polymerase chain reaction (RT-qPCR). Primary human fetal astrocytes were cultured under in vitro stress conditions and transfection of a miR mimic was used to better understand how altered levels of miR-210 affect astrocyte function. The astrocytic response to stress was studied using qPCR, enzyme-linked immunosorbent assays (ELISAs), measurement of released lactate, and Seahorse. Here, we measured miR expression levels in astrocytes around human ischemic stroke lesions and observed differential expression of miR-210 in chronic stroke astrocytes compared to astrocytes from neurological control tissue. We also identified increased expression of miR-210 in mouse white matter tissue around middle cerebral artery occlusion (MCAO) brain lesions. We aimed to understand the role of miR-210 in primary human fetal astrocytes by developing an in vitro assay of hypoxic, metabolic, and inflammatory stresses. A combination of hypoxic and inflammatory stresses was observed to upregulate miR-210 expression. Transfection with miR-210-mimic (210M) increased glycolysis, enhanced lactate export, and promoted an anti-inflammatory transcriptional and translational signature in astrocytes. Additionally, 210M transfection resulted in decreased expression of complement 3 (C3) and semaphorin 5b (Sema5b). We conclude that miR-210 expression in human astrocytes is modulated in response to ischemic stroke disease and under in vitro stress conditions, supporting a role for miR-210 in the astrocytic response to disease conditions. Further, the anti-inflammatory and pro-glycolytic impact of miR-210 on astrocytes makes it a potential candidate for further research as a neuroprotective agent.
Sections du résumé
BACKGROUND
BACKGROUND
Astrocytes are the most numerous glial cell type with important roles in maintaining homeostasis and responding to diseases in the brain. Astrocyte function is subject to modulation by microRNAs (miRs), which are short nucleotide strands that regulate protein expression in a post-transcriptional manner. Understanding the miR expression profile of astrocytes in disease settings provides insight into the cellular stresses present in the microenvironment and may uncover pathways of therapeutic interest.
METHODS
METHODS
Laser-capture microdissection was used to isolate human astrocytes surrounding stroke lesions and those from neurological control tissue. Astrocytic miR expression profiles were examined using quantitative reverse transcription polymerase chain reaction (RT-qPCR). Primary human fetal astrocytes were cultured under in vitro stress conditions and transfection of a miR mimic was used to better understand how altered levels of miR-210 affect astrocyte function. The astrocytic response to stress was studied using qPCR, enzyme-linked immunosorbent assays (ELISAs), measurement of released lactate, and Seahorse.
RESULTS
RESULTS
Here, we measured miR expression levels in astrocytes around human ischemic stroke lesions and observed differential expression of miR-210 in chronic stroke astrocytes compared to astrocytes from neurological control tissue. We also identified increased expression of miR-210 in mouse white matter tissue around middle cerebral artery occlusion (MCAO) brain lesions. We aimed to understand the role of miR-210 in primary human fetal astrocytes by developing an in vitro assay of hypoxic, metabolic, and inflammatory stresses. A combination of hypoxic and inflammatory stresses was observed to upregulate miR-210 expression. Transfection with miR-210-mimic (210M) increased glycolysis, enhanced lactate export, and promoted an anti-inflammatory transcriptional and translational signature in astrocytes. Additionally, 210M transfection resulted in decreased expression of complement 3 (C3) and semaphorin 5b (Sema5b).
CONCLUSIONS
CONCLUSIONS
We conclude that miR-210 expression in human astrocytes is modulated in response to ischemic stroke disease and under in vitro stress conditions, supporting a role for miR-210 in the astrocytic response to disease conditions. Further, the anti-inflammatory and pro-glycolytic impact of miR-210 on astrocytes makes it a potential candidate for further research as a neuroprotective agent.
Identifiants
pubmed: 34991629
doi: 10.1186/s12974-021-02373-y
pii: 10.1186/s12974-021-02373-y
pmc: PMC8740343
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10Subventions
Organisme : Progressive MS Alliance
ID : PA-1604-08459
Informations de copyright
© 2022. The Author(s).
Références
Nature. 2014 May 8;509(7499):189-94
pubmed: 24776795
Exp Neurol. 2004 Mar;186(1):70-7
pubmed: 14980811
Nature. 2020 Feb;578(7796):593-599
pubmed: 32051591
Cytokine Growth Factor Rev. 2011 Jun;22(3):121-30
pubmed: 21802343
J Immunol. 2005 Oct 1;175(7):4320-30
pubmed: 16177072
Front Genet. 2020 Jan 28;10:1330
pubmed: 32047509
J Biol Chem. 2002 Jan 18;277(3):1933-40
pubmed: 11707454
Nat Neurosci. 2021 Mar;24(3):312-325
pubmed: 33589835
J Cell Physiol. 2019 May;234(5):5451-5465
pubmed: 30471116
Cell Rep. 2020 Sep 1;32(9):108092
pubmed: 32877674
Sci Rep. 2016 Aug 26;6:32095
pubmed: 27561791
Cold Spring Harb Perspect Biol. 2015 Apr 15;7(6):
pubmed: 25877220
Sci Rep. 2019 Oct 31;9(1):15735
pubmed: 31672997
Sci Rep. 2017 Oct 10;7(1):12904
pubmed: 29018286
Stroke. 2004 Mar;35(3):616-21
pubmed: 14963288
Ann Neurol. 2017 Jun;81(6):811-824
pubmed: 28470695
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):E756-65
pubmed: 23388633
Neuroreport. 2000 Jan 17;11(1):89-91
pubmed: 10683836
Genome Biol. 2009;10(6):R64
pubmed: 19531210
Nature. 2017 Jan 26;541(7638):481-487
pubmed: 28099414
Front Genet. 2015 Dec 02;6:340
pubmed: 26697058
Front Mol Neurosci. 2017 Dec 19;10:427
pubmed: 29311817
Stem Cells. 2015 Apr;33(4):1333-44
pubmed: 25537659
J Neurosci. 2012 May 2;32(18):6391-410
pubmed: 22553043
Oncogene. 2010 Jul 29;29(30):4362-8
pubmed: 20498629
FEBS Lett. 2012 Apr 24;586(8):1201-7
pubmed: 22575656
Neurol Res. 2015 Sep;37(9):803-8
pubmed: 26038835
Metab Brain Dis. 2015 Feb;30(1):25-30
pubmed: 25034458
Brain. 2008 Jul;131(Pt 7):1722-35
pubmed: 18515320
J Child Neurol. 2011 Sep;26(9):1193-8
pubmed: 21628695
Hum Exp Toxicol. 2000 Nov;19(11):641-9
pubmed: 11211243
J Immunol. 1993 Apr 1;150(7):2659-67
pubmed: 8454848
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13606-11
pubmed: 16938869
J Biol Chem. 2009 Nov 27;284(48):33161-8
pubmed: 19721136
Science. 2012 Jul 20;337(6092):358-62
pubmed: 22745251
Cell Transplant. 2014;23(4-5):541-7
pubmed: 24816449
J Neurol Sci. 2008 Aug 15;271(1-2):104-9
pubmed: 18479710
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6415-20
pubmed: 18434550
Neural Dev. 2009 May 23;4:18
pubmed: 19463192
Acta Neuropathol. 2004 Dec;108(6):524-30
pubmed: 15517310
Methods Mol Biol. 2013;1041:199-211
pubmed: 23813381
Glia. 2005 Jan 15;49(2):161-76
pubmed: 15472994
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Stroke. 2012 Jan;43(1):211-9
pubmed: 22020035
Stroke. 2008 Mar;39(3):959-66
pubmed: 18258830
Neural Regen Res. 2015 Oct;10(10):1604-11
pubmed: 26692857
Cell Death Dis. 2020 Sep 9;11(9):731
pubmed: 32908121
Neurosci Lett. 2015 May 6;594:99-104
pubmed: 25827488
J Neuropathol Exp Neurol. 2003 Jan;62(1):25-33
pubmed: 12528815
Neurotox Res. 2020 Aug;38(2):330-343
pubmed: 32415527
Methods Enzymol. 2014;542:91-114
pubmed: 24862262
J Neuropathol Exp Neurol. 2016 Feb;75(2):156-66
pubmed: 26802178
Nature. 2013 Dec 19;504(7480):394-400
pubmed: 24270812
Cell Res. 2020 Apr;30(4):300-314
pubmed: 32132672
BMC Syst Biol. 2011 Oct 13;5:162
pubmed: 21995951
J Interferon Cytokine Res. 2019 Jun;39(6):321-330
pubmed: 30998423
Tohoku J Exp Med. 2012;228(1):27-41
pubmed: 22892400
J Neuroinflammation. 2020 Apr 16;17(1):119
pubmed: 32299492
J Neuropathol Exp Neurol. 2019 Dec 1;78(12):1130-1146
pubmed: 31665376
PLoS One. 2014 Dec 12;9(12):e115241
pubmed: 25501359
Nucleic Acids Res. 2020 Jan 8;48(D1):D142-D147
pubmed: 31691816
J Cereb Blood Flow Metab. 2013 Aug;33(8):1197-206
pubmed: 23632968